Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis

Background: Bronchiectasis is a chronic inflammation of the bronchi with recurrent infections and hemoptysis. The MAGELLAN study compared oral rivaroxaban, 10 mg once daily (QD), for 35 ± 4 days with subcutaneous enoxaparin 40 mg QD for 10 ± 4 days followed by placebo for 25 ± 4 days to prevent veno...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipardi, Concetta, Elliott, C. Gregory, Sugarmann, Chiara L., Haskell, Lloyd, Spyropoulos, Alex C., Raskob, Gary E., Xu, Jianfeng, Lu, Wentao, Marsigliano, Jessica, Spiro, Theodore, Yuan, Zhong, Wu, Shujian, Barnathan, Elliot S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Manuscript
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559236/
https://www.ncbi.nlm.nih.gov/pubmed/34719984
http://dx.doi.org/10.1177/10760296211053316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559236/
https://www.ncbi.nlm.nih.gov/pubmed/34719984
http://dx.doi.org/10.1177/10760296211053316

Ejemplares similares